Background: Precision Cancer Therapies
PACT Pharma, a leader in the fields of cancer immunology and cell therapy in collaboration with a UCLA team, presented new data demonstrating for the first time the ability to identify mutation targets unique to each patient’s cancer and verify the cancer specificity of multiple cloned T cell receptors.
Each patient’s cancer has a private signature of mutations, creating an opportunity to develop fully personalized immune therapies that have the potential to eradicate tumor cells.
Defining these caner mutation targets for each patient, known as neoantigens, enables the company to use its proprietary gene engineering technologies to manufacture an immune cell therapy product for each patient with cancer. The company recently presented this ability at the AACR’s Special Conference on Immune Cell Therapies for Cancer.
Phase I Study
The company has begun enrolling patients with advanced solid tumors into a Phase 1 dose escalation study of NetoTCR-P1, an autologous gene-edited TCR T cell product that targets personalized neoantigens. The study is the first-in-human, single-arm, open-label Phase 1a/1b study to determine the safety, feasibility,...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).